MedTrace Logo

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

NCT02876978 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-08-24

No results posted yet for this study

Summary

The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)

Conditions

  • Lung Squamous Cell Carcinoma

Interventions

GENETIC

CAR-GPC3 T Cells

Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.

DRUG

Fludarabine

30 mg/m\^2/day x 4 days

DRUG

Cyclophosphamide

500 mg/m\^2/day x 2 days

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiang Liyan, MD · Shanghai Chest Hospital,Shanghai Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-10-31
Completion
2019-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876978 on ClinicalTrials.gov